Abstract 662P
Background
IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the domain of SIRPα at the N-terminus of heavy chains. Blockade of PD-L1 and CD47- SIRPα pathway fully activate macrophages and induce enhanced ADCP and ADCC activity, leading to potent integrated antitumor response.
Methods
This is an open-label, first in human, dose escalation and dose expansion phase1 study to evaluate the safety, RP2D/MTD and anti-tumor effect for IMM2520 in pts with advanced solid tumor. The dose escalation was designed with an accelerated titration at first dose level followed by standard 3+3 design. IMM2520 was administered weekly in a 28 day-cycle. Additional patients will be enrolled for potential RP2D to identify optimized dose level. Here we report results in ongoing dose escalation stage.
Results
As of 4 Apr 2024, 18 patients (pts) were treated at 5 dose levels (from 0.1mpk to 4mpk). Most pts (61%) previously received ≥ 3 lines of systemic anti-tumor therapy, including 9 (50%) pts with PD-(L)1 therapy history. No DLTs were observed yet. All pts reported treatment-related adverse event (TRAE), of which 10 (56%) pts were ≥ Grade 3. The most common TRAE of any grade was platelet decreased (89%), anemia (67%), white blood cell decreased (56%) and infusion-related reaction (IRR) (56%). The most common TRAE of ≥ Grade 3 was lymphocyte decreased (50%), platelet decreased (33%) and anorexia (5.6%). No AE leading to treatment discontinuation was observed. Of 11 efficacy evaluable pts,1 unconfirmed partial response (PR) in small cell lung cancer (SCLC) at 2mpk (with 2 previous lines of therapy including immunotherapy and negative PD-L1 expression) and 5 stable disease (SD) were observed, including 1 cervical cancer with 21.1% tumor shrinkage and 1 colorectal cancer with 11.1% tumor shrinkage. Pharmacodynamic biomarker included CD47 Target occupancy (TO) on peripheral circulating CD3+T cells using flow cytometry analysis. The rate of CD47 TO was mild and exhibits a dose-dependent trend.
Conclusions
IMM2520 showed tolerance at the evaluated doses and preliminary anti-tumor activity in advanced solid tumor, especially for SCLC. The dose escalation is ongoing.
Clinical trial identification
NCT05780307.
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Funding
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Disclosure
A. Wu, X. Zhao, Z. Wang, Q. Lu: Financial Interests, Personal, Full or part-time Employment: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. W. Tian: Financial Interests, Personal, Stocks or ownership: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. All other authors have declared no conflicts of interest.
Resources from the same session
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01